Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dynamic imaging: scintimammography

M Salvatore1, S Del Vecchio

  • 1Nuclear Medicine, National Research Council CNR, and Department of Biomorphological and Functional Sciences, Federico II University, Naples, Italy.

European Journal of Radiology
|July 4, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

LAG3 as a potential biomarker in breast cancer: integrated tissue and peripheral blood analysis reveals clinical and pathomic insights in triple-negative disease.

Journal of translational medicine·2026
Same author

LINC00958 as new diagnostic and prognostic biomarker of childhood acute lymphoblastic leukaemia of B cells.

Frontiers in oncology·2024
Same author

Peripheral blood BDNF and soluble CAM proteins as possible markers of prolonged disorders of consciousness: a pilot study.

Scientific reports·2024
Same author

Hidden CFSPID in CF patient registries? The Italian CF Registry experience.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2023
Same author

PET/MRI for staging patients with Hodgkin lymphoma: equivalent results with PET/CT in a prospective trial.

Annals of hematology·2021
Same author

Patterns of repeated diagnostic testing for COVID-19 in relation to patient characteristics and outcomes.

Journal of internal medicine·2020

Radionuclide breast imaging using 99mTc-MIBI shows promise for diagnosing suspicious lesions and predicting chemotherapy response in breast cancer patients. However, it has limitations for nonpalpable abnormalities, requiring histologic confirmation.

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiology

Background:

  • Mammography is the primary breast cancer screening tool, but emerging techniques like radionuclide imaging offer complementary diagnostic capabilities.
  • Radionuclide imaging, particularly with 99mTc-MIBI, is being investigated for differential diagnosis of malignant and benign breast lesions, especially in complex cases like dense breasts or post-treatment changes.

Purpose of the Study:

  • To evaluate the role of radionuclide breast imaging in managing women with mammographically suspicious breast lesions.
  • To assess the utility of 99mTc-MIBI for diagnosing breast lesions and predicting response to chemotherapy by evaluating multidrug resistance phenotype.

Main Methods:

  • Review of current challenges and applications of radionuclide breast imaging, focusing on 99mTc-MIBI.

Related Experiment Videos

  • Analysis of sensitivity and specificity rates of 99mTc-MIBI scintigraphy for palpable and nonpalpable breast lesions.
  • In vivo kinetic analysis of 99mTc-MIBI efflux to correlate with P-glycoprotein (P-gp) levels and predict neoadjuvant chemotherapy response in breast cancer patients.

    • Main Results:

    • 99mTc-MIBI scintigraphy demonstrates high sensitivity (92%) and specificity (89%) for palpable breast lesions but lower sensitivity for nonpalpable lesions (<1 cm), necessitating histologic diagnosis.
    • A significant correlation (r=0.62, p<0.001) was found between in vivo 99mTc-MIBI efflux rates and in vitro P-gp levels, indicating its suitability for assessing multidrug resistance.
    • Rapid tumor clearance of 99mTc-MIBI (< or = 204 min) predicted a lack of response to neoadjuvant chemotherapy in advanced breast cancer patients.

    Conclusions:

    • Radionuclide breast imaging with 99mTc-MIBI is valuable for differentiating benign from malignant breast lesions, guiding treatment decisions.
    • Functional imaging of the multidrug resistance phenotype using 99mTc-MIBI can help predict chemotherapy response and personalize treatment regimens.
    • While effective for palpable lesions, 99mTc-MIBI imaging requires integration with other diagnostic methods, especially for nonpalpable abnormalities.